Log In
BCIQ
Print this Print this
 

AGT-182

  Manage Alerts
Collapse Summary General Information
Company ArmaGen Inc.
DescriptionFusion protein of iduronate-2-sulfatase (IDS) that crosses the blood-brain barrier by binding to insulin receptors (INSR)
Molecular Target Insulin receptor (INSR)
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I/II
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis II (MPS II, Hunter syndrome)
Regulatory Designation U.S. - Orphan Drug (Treat mucopolysaccharidosis II (MPS II, Hunter syndrome));
EU - Orphan Drug (Treat mucopolysaccharidosis II (MPS II, Hunter syndrome))
PartnerShire plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$225.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/23/2014

$225.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today